---
id: 144
title: Coxiella burnetii (Q Fever)
category: organisms
subcategory: intracellular_bacteria
tags: [Q-fever, Coxiella, endocarditis, doxycycline, livestock]
difficulty: medium
---

## Question

How is Q fever managed? Use the **"Acute = Doxycycline × 14 Days, Chronic Endocarditis = Doxy + Hydroxychloroquine × 18 Months"** framework.

## Answer

### ***Coxiella burnetii* (Q Fever) Overview:**

**Transmission:**
- **Inhalation** of aerosols from infected animals (cattle, sheep, goats)
- **No tick vector** (unlike other rickettsiae) - airborne spread
- **Occupational:** Farmers, veterinarians, slaughterhouse workers, lab workers
- **Highly infectious:** Single organism can cause infection

### **Clinical Syndromes:**

**Acute Q Fever:**

**Asymptomatic (60%):**
- Most infections subclinical

**Symptomatic (40%):**
- **Febrile illness:** Acute onset fever, severe headache, chills, myalgia
- **Pneumonia** (30-50%): Atypical pneumonia, CXR may show rounded opacities
- **Hepatitis** (30-60%): Elevated transaminases (>5× ULN), hepatomegaly, granulomas on biopsy
- **"Culture-negative" endocarditis:** Rare in acute phase
- **No rash** (unlike other rickettsiae)

**Chronic Q Fever (1-5% of Acute Infections):**

**Endocarditis (Most Common):**
- **Subacute/chronic** presentation (months to years after acute infection)
- **Risk factors:** Pre-existing valvular disease, prosthetic valves, immunosuppression
- **Large vegetations**, negative blood cultures
- **Diagnostic:** High anti-phase I IgG titers (>1:800)

**Other Chronic Manifestations:**
- **Vascular infections:** Aneurysm, vascular graft infections
- **Osteomyelitis**
- **Chronic hepatitis**

### **Diagnosis:**

**Serology (Gold Standard):**
- **Acute Q fever:** Anti-phase II IgG/IgM (phase II > phase I)
  - **IgM >1:50** OR **IgG 4-fold rise** OR **IgG >1:200**
- **Chronic Q fever:** Anti-phase I IgG **>1:800** (phase I > phase II)

**PCR:**
- Blood, tissue (valve, vascular graft)
- More sensitive than culture

**Culture:**
- **Requires BSL-3 facility** (highly infectious, lab hazard)
- Not routinely performed

**Imaging:**
- **CXR:** Pneumonia (rounded opacities, pleural effusion)
- **Echocardiography:** TEE if suspected endocarditis (vegetations)

### **Treatment:**

**Acute Q Fever:**
- **Doxycycline 100mg PO BID × 14 days**
- **Start empirically** if suspected (serology negative early)
- **Alternative:** Fluoroquinolones (levofloxacin, moxifloxacin) if doxycycline contraindicated

**Chronic Q Fever Endocarditis:**
- **Doxycycline 100mg PO BID** + **hydroxychloroquine 200mg PO TID** × **≥18 months**
- **Rationale:** Hydroxychloroquine alkalinizes phagolysosomes → improves doxycycline activity
- **Monitor:** Anti-phase I IgG titers (should decline), hydroxychloroquine levels (2-4 weeks after starting, target 0.8-1.2 mcg/mL), ophthalmology exams (retinal toxicity)
- **Surgery:** Often required (large vegetations, heart failure, emboli)

**Chronic Q Fever (Vascular Infections):**
- **Doxycycline + hydroxychloroquine × ≥18-24 months**
- **Surgery:** Often required (infected aneurysm, vascular graft)

**Q Fever in Pregnancy:**
- **Acute:** TMP-SMX throughout pregnancy (doxycycline contraindicated)
- **Chronic or high-risk:** TMP-SMX + monitor anti-phase I IgG titers, continue postpartum with doxycycline + hydroxychloroquine
- **Risk:** Adverse pregnancy outcomes (miscarriage, preterm birth, IUGR)

## Key Points

### **Acute vs Chronic Q Fever Serology:**

| Feature | Acute Q Fever | Chronic Q Fever (Endocarditis) |
|---------|---------------|-------------------------------|
| **Phase II antibodies** | **High** (>phase I) | Low |
| **Phase I antibodies** | Low | **High (>1:800)** |
| **IgM** | Elevated | May be negative |
| **IgG** | Elevated (phase II > phase I) | **Markedly elevated** (phase I >1:800) |

### **Why Hydroxychloroquine:**
- **Alkalinizes phagolysosomes** (where *C. burnetii* resides)
- **Improves doxycycline efficacy** against intracellular organisms
- **Monitor:** Hydroxychloroquine levels (target 0.8-1.2 mcg/mL), ophthalmology exams (retinal toxicity risk)

### **No Rash:**
- **Unlike other rickettsiae** (RMSF, ehrlichiosis), Q fever **does NOT cause rash**
- Helpful clinical clue

### **Culture-Negative Endocarditis:**
- ***C. burnetii* = common cause** (along with *Bartonella*, *Brucella*, HACEK, nutritionally variant streptococci)
- **Serology essential** (anti-phase I IgG >1:800)

### **Post-Q Fever Fatigue Syndrome:**
- **Persistent fatigue** (>6 months after acute infection)
- **10-20% of acute Q fever patients**
- **No proven treatment** (supportive care)
- **Not due to persistent infection** (antibiotics ineffective)

### **Prevention:**
- **Occupational:** PPE, proper handling of animal products, pasteurization of milk
- **Vaccine:** Available in Australia (not FDA-approved in US), used for high-risk occupations

### **High-Risk Groups for Chronic Q Fever:**
- **Pre-existing valvular disease** (rheumatic heart disease, bicuspid aortic valve)
- **Prosthetic valves**
- **Immunosuppression**
- **Pregnancy**
- **Vascular grafts/aneurysms**

### **Clinical Pearls:**
- **Acute Q fever:** Doxycycline 100mg BID × 14 days
- **Chronic endocarditis:** Doxycycline + hydroxychloroquine × ≥18 months
- **No rash** (unlike other rickettsiae)
- **High anti-phase I IgG (>1:800)** = chronic Q fever endocarditis
- **Pneumonia + hepatitis** + livestock exposure = Q fever
- **Culture-negative endocarditis** with high serology = *C. burnetii*
- **Monitor hydroxychloroquine levels** and ophthalmology (retinal toxicity)

## Sources

- [CDC: Q Fever Guidelines 2024]
- [European Heart Journal: Q Fever Endocarditis 2023]

## Media

N/A
